

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



June 15, 2026

For Immediate Release

Company name: Kitazato Corporation
Representative: Futoshi Inoue President, CEO
(Code number: 368A, Prime Market of Tokyo Stock Exchange)
Contact: Masanobu Suzuki
Director, General Manager of Corporate Planning Department
(Tel. +81-545-65-7122)

Notice Regarding Business Alliance and Establishment of a Joint Venture Company (Consolidated Subsidiary) in India

Kitazato Corporation hereby announces that at the meeting of its Board of Directors held on June 15, 2026, it resolved to enter into a joint venture agreement with Repro Lifesciences LLP and establish a joint venture company in India for the purpose of strengthening regulatory compliance, market understanding, and customer support in the country. Details are as follows.

1. Purpose and Details of the Business Alliance and Establishment of the Joint Venture Company

India is one of the key markets expected to achieve significant growth in the future. The Company has been working to appropriately manage product registrations and establish a framework for market understanding, customer engagement, and support in the country.

Accordingly, the Company has decided to enter into a business alliance with Repro Lifesciences LLP, which has an established network in the fertility treatment sector in India, and to establish a joint venture company.

The joint venture company will play a role in strengthening the Company's investment in the Indian market while enabling it to fulfill its responsibilities as a manufacturer more effectively.

Through the establishment of a local entity, the Company aims to deepen its understanding of the market and further enhance promotional and technical support activities, thereby expanding its business in India.

2. Overview of the Joint Venture Company

(1) N a m e	Kitazato India Private Limited (tentative)
(2) L o c a t i o n	India
(3) T i t l e a n d N a m e o f R e p r e s e n t a t i v e	Managing Director Jatin Goel
(4) B u s i n e s s D e s c r i p t i o n	Regulatory compliance, market understanding, and improving customer relationship with technical support
(5) C a p i t a l	INR 5,000,000 (approximately JPY 8.5 million)
(6) D a t e o f E s t a b l i s h m e n t	July 2026 (planned)
(7) N e t A s s e t s	Not applicable (newly established company)
(8) T o t a l A s s e t s	Not applicable (newly established company)
(9) E q u i t y O w n e r s h i p R a t i o	Kitazato Corporation 51%, Repro Lifesciences LLP 49%

(10) Relationship between the Company and the Joint Venture Company	Capital relationship	The Company plans to subscribe for 51% of the shares of the joint venture company.
	Personnel relationship	The Company plans to appoint two directors and one corporate auditor to the joint venture company.
	Business relationship	Business transactions are expected to arise between the parties in the future.

*The JPY amount is calculated using an exchange rate of JPY 1.70 per INR 1.

3. Overview of the Alliance Partner

(1) Name	Repro Lifesciences LLP	
(2) Location	India	
(3) Title and Name of Representative	Designated Partner Jatin Goel	
(4) Business Description	Sales of fertility treatment-related products and related businesses	
(5) Date of Establishment	July 2, 2024	
(6) Capital	INR 2,000,000 (approximately JPY 3.4 million)	
(7) Relationship between the Company and the Alliance Partner	Capital relationship	None.
	Personnel relationship	None.
	Business relationship	None.
	Status as a Related Party	Although there are currently no applicable matters, Mr. Jatin Goel is expected to serve as the representative of the joint venture company.

*As the company was recently established, is organized as a Limited Liability Partnership (LLP) under Indian law and does not issue shares, and has a relatively small business scale, information regarding its financial position and operating results for the past three fiscal years has been omitted.

4. Schedule

(1) Date of Board Resolution	June 15, 2026
(2) Date of Execution of Agreement	June 16, 2026 (planned)
(3) Date of Establishment	July 2026 (planned)
(4) Commencement of Operations	October 2026 (planned)

5. Future Outlook

The impact of this matter on the Company's consolidated financial results for the fiscal year ending March 31, 2027 is expected to be immaterial. The Company will promptly disclose any matters that should be announced in the future.